Literature DB >> 27720954

In-vitro investigation regarding the effects of Gelucire® 44/14 and Labrasol® ALF on the secretory intestinal transport of P-gp substrates.

Océane Dubray1, Vincent Jannin2, Fréderic Demarne2, Yann Pellequer1, Alf Lamprecht3, Arnaud Béduneau4.   

Abstract

In this present study, the secretory transport of P-gp substrates, rhodamine 123 and digoxin, was evaluated using a Caco-2/HT29-MTX co-culture characterized by an efflux mechanism and a paracellular permeability closer to the human intestinal barrier compared to the Caco-2 monolayer gold standard. The influence of simulated intestinal fluids termed FeSSIF and FaSSIF on the intestinal absorption was also assessed in comparison with a conventional saline buffer. Labrasol® ALF and Gelucire® 44/14 in saline buffer significantly decreased to 83% and 62%, the P-gp-mediated transport of rhodamine 123 across the co-culture, respectively. The effects of Gelucire® 44/14 were much more exacerbated with the Caco-2 monolayer model with a reduced permeability to 34% but they were partially reversed in the co-culture with FeSSIF. The modulation by the lipid excipients of digoxin secretory transport across the Caco-2 monolayer and the co-culture was reduced compared with the rhodamine 123. This work also emphasizes the numerous parameters that have to be considered for predicting accurately the effects of potential P-gp inhibitors including the in-vitro model, the incubation media and the intrinsic properties of P-gp substrates. Copyright Â
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Caco-2/HT29-MTX co-culture; Digoxin; Gelucire(®); Intestinal barrier; Labrasol(®); P-glycoprotein; Permeability

Mesh:

Substances:

Year:  2016        PMID: 27720954     DOI: 10.1016/j.ijpharm.2016.10.012

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  4 in total

1.  Clinical utility of ABCB1 and ABCG2 genotyping for assessing the clinical and pathological response to FAC therapy in Mexican breast cancer patients.

Authors:  Eneida Turiján-Espinoza; Víctor Manuel Ruíz-Rodríguez; Edith Elena Uresti-Rivera; Ernesto Martínez-Leija; José de Jesús Zermeño-Nava; Arturo Guel-Pañola; Silvia Romano-Moreno; Juan Manuel Vargas-Morales; Diana Patricia Portales-Pérez
Journal:  Cancer Chemother Pharmacol       Date:  2021-03-19       Impact factor: 3.333

2.  Formulation of Novel Liquid Crystal (LC) Formulations with Skin-Permeation-Enhancing Abilities of Plantago lanceolata (PL) Extract and Their Assessment on HaCaT Cells.

Authors:  Dóra Kósa; Ágota Pető; Ferenc Fenyvesi; Judit Váradi; Miklós Vecsernyés; Sándor Gonda; Gábor Vasas; Pálma Fehér; Ildikó Bácskay; Zoltán Ujhelyi
Journal:  Molecules       Date:  2021-02-15       Impact factor: 4.411

3.  Self-Assembled Lipid Nanoparticles for Oral Delivery of Heparin-Coated Iron Oxide Nanoparticles for Theranostic Purposes.

Authors:  Eleonora Truzzi; Chiara Bongio; Francesca Sacchetti; Eleonora Maretti; Monica Montanari; Valentina Iannuccelli; Elena Vismara; Eliana Leo
Journal:  Molecules       Date:  2017-06-09       Impact factor: 4.411

4.  Modified mixed nanomicelles with collagen peptides enhanced oral absorption of Cucurbitacin B: preparation and evaluation.

Authors:  Lan Tang; Lulu Fu; Zhuanfeng Zhu; Yan Yang; Boxuan Sun; Weiguang Shan; Zhenhai Zhang
Journal:  Drug Deliv       Date:  2018-01-01       Impact factor: 6.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.